Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620384 · ClinicalTrials.gov registry record · Phase 3
Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.
A Phase 3 study, sponsored by Aultman Health Foundation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT02620384: Clinical Trial Phase 3 study, sponsored by Aultman Health Foundation.
NCT02620384 is a Phase 3 study that was terminated before completion, run by Aultman Health Foundation. The registered enrollment target is 147 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02620384, a Phase 3 study, was terminated before completion, sponsored by Aultman Health Foundation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine efficacy of metolazone as synergistic therapy with Lasix in patients with acute decompensated heart failure. This will be a single center double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day for 2 days compared to placebo in patients admitted with acute decompensated heart failure.
Primary Outcome
Total urinary output in milliliters (ml) at 48 hours. Measurement timing began with administration of first dose of investigational product, ended 48 hours later.
Interventions
- DRUG Experimental: Placebo
- DRUG Experimental: Metolazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2017-12-29 |
| Phase | Phase 3 |
Why NCT02620384 stopped before completion
NCT02620384 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Experimental: Placebo is the first listed.
NCT02620384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02620384 about?
NCT02620384 is a clinical study titled "Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.". The primary objective of the study is to determine efficacy of metolazone as synergistic therapy with Lasix in patients with acute decompensated heart failure. This will be a single center double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day for 2 d...
What is the current status of trial NCT02620384?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2015-10-01. Estimated completion is 2017-12-29.
What interventions are being tested in trial NCT02620384?
The interventions under investigation include: Experimental: Placebo (DRUG), Experimental: Metolazone (DRUG).
Who is sponsoring clinical trial NCT02620384?
This trial is sponsored by Aultman Health Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02620384's enrollment target sits among peer trials
147 1550th of 2000 higher than 450 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI